Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma

00:16 EST 21 Nov 2017 | ChinaBio Today

Canada's Acasti Pharma signed a $133 million non-binding term sheet with an unnamed China pharma for China/Asia rights to its hypertriglyceridemia drug candidate. CaPre, a prescription medication, is a highly concentrated omega-3 phospholipid derived from krill. Acasti believes CaPre is more readily absorbed into the body than competing omega-3 products. Earlier this year, Acasti announced Phase III trials of the candidate, which will use the abbreviated 505(b)(2) pathway for approval in the US. More details....

Stock Symbol: (NSDQ/TSX: ACST)

Share this with colleagues:

Original Article: Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma


More From BioPortfolio on "Canada's Acasti Signs $133 Million Non-Binding Term Sheet with China Pharma"

Quick Search


Relevant Topics

Hyperlipidemia - high cholesterol (hypercholesterolaemia)
Hyperlipidemia involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Lipids are transported in a protein capsule, the size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Prescription Drugs
A prescription drug (also prescription medication or prescription medicine) is a licensed medicine that is regulated by legislation to require a medical prescription before it can be obtained. The term is used to distinguish it from over-the-counter drug...